Cancer Clinical Trial
— MioOfficial title:
Metacognitive Intervention in Youth With Oncological Disease - the Mio Study
The aim of the Mio-Study is to address the current lack of effective treatment options to reduce cognitive and physical long-term problems in adolescents with cancer. Through the use of the Mio-App, cognitive and physical development will be strengthened and metacognitive thinking and awareness will increase. The Mio-App for adolescence with cancer will include a combination of cognitive and physical training tasks and prospective as well as retrospective metacognitive questions. In a randomized controlled trial, the App will be analysed for its efficacy on metacognitive thinking and executive functions. In particular, the investigators are interested in factors that affect the efficacy of the training program such as compliance, age, sex or the presence of fatigue. This study will give insight into the role of metacognition in cognitive and physical performance and will foster the development of adolescents with cancer in the long-term.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | April 1, 2026 |
Est. primary completion date | April 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 16 Years |
Eligibility | Inclusion Criteria: - Informed consent as documented by signature (see Informed Consent Form) of participants and / or parents / legal guardians - Age 10-16 years - A diagnosis of cancer either with or without central nervous system (CNS) involvement - Treatment of cancer including either radiation, chemotherapy and/ or surgical tumor removal - Three months before to three months after the end of cancer treatment - German or French speaking Exclusion Criteria: - Any other instable neurological condition (e.g. epilepsy) - A severe psychiatric disease (e.g., eating disorder) or severe learning disability - Known or suspected non-compliance - Drug or alcohol abuse - Inability to follow the procedures of the study, e.g. due to language problems - Enrolment of the investigator, his/her family members, employees and other dependent persons |
Country | Name | City | State |
---|---|---|---|
Switzerland | Insespital, University Hospital Bern | Bern |
Lead Sponsor | Collaborator |
---|---|
Insel Gruppe AG, University Hospital Bern | University of Bern |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Physical Self-Description Questionnaire (PSDQ-S) | Short version, Likert scale ranging from 1 to 6. Higher scores mean better outcome. | At baseline; immediately (up to 1 week) after the training or waiting period; at 3-months follow-up. | |
Other | Strengths and Difficulties Questionnaire (SDQ) | The total value is between 0 -40. Lower scores mean better outcome. | At baseline; immediately (up to 1 week) after the training or waiting period; at 3-months follow-up. | |
Other | Pediatric quality of life multidimensional fatigue scale (PedsQL-MFS) | 5-point Likert scale ranging from 0 to 4. Higher scores mean better outcome. | At baseline; immediately (up to 1 week) after the training or waiting period; at 3-months follow-up. | |
Primary | Junior Metacognitive Awareness Inventory | Change from baseline in Junior Metacognitive Awareness Inventory to 3-months follow-up. Raw values ranging 18-90. Higher scores mean better outcome. | At baseline; immediately (up to 1 week) after the training or waiting period; at 3-months follow-up | |
Secondary | Wechsler Intelligence Scale For Children: 5th Ed (WISC-V) | Indices ranging from 0 to 155. Higher scores mean better outcome. | At baseline; immediately (up to 1 week) after the training or waiting period. | |
Secondary | Color-Word Interference Test | Scaled Scores ranging from 1 to 19. Higher scores mean better outcome. | At baseline; immediately (up to 1 week) after the training or waiting period. | |
Secondary | Tower of Hanoi (D-KEFS) | Scaled Scores ranging from 1 to 19. Higher scores mean better outcome. | At baseline; immediately (up to 1 week) after the training or waiting period. | |
Secondary | Verbal learning and memory test (VLMT) | Percentile ranks ranging from 0-100. Higher scores mean better outcome. | At baseline; immediately (up to 1 week) after the training or waiting period. | |
Secondary | Pattern learning (Basic-MLT) | Percentile ranks ranging from 0-100. Higher scores mean better outcome. | At baseline; immediately (up to 1 week) after the training or waiting period. | |
Secondary | German Motor Performance Test (DMT) | Percentile ranks ranging from 0-100. Higher scores mean better outcome. | At baseline; immediately (up to 1 week) after the training or waiting period. | |
Secondary | Behaviour Rating Inventory of Executive Function | Percentile ranks ranging from 0-100. Higher scores mean better outcome. | At baseline; immediately (up to 1 week) after the training or waiting period; at 3-months follow-up. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|